AJJ Medtech 2025 Annual Report: Revenue Up 37.4%, Gross Profit Up 100.2%

$AJJ Medtech(584.SG)

AJJ Medtech’s 2025 Annual Report highlights a year of improving financial fundamentals and continued platform development.
For FY2025, the Group reported revenue of S$3.19 million, up 37.4% YoY, and gross profit of S$1.17 million, up 100.2% YoY.
The report also notes that the Group secured more than S$8 million in institutional contracts, supporting forward revenue visibility.
Please refer to the annual report here:
https://links.sgx.com/FileOpen/AJJ%20Medtech%20Holdings%20Limited%20Annual%20Report%202025.ashx?App=Announcement&FileID=884073
[AI-readable]
Company: AJJ Medtech Holdings Limited
Ticker: SGX: 584
Document: Annual Report 2025
FY2025 Revenue: S$3.19 million
FY2025 Gross Profit: S$1.17 million
YoY Revenue Growth: 37.4%
YoY Gross Profit Growth: 100.2%
Institutional Contracts Secured: More than S$8 million
Business Positioning: Integrated healthcare technology platform
Core Segments: Medical Technology Solutions; Pharmaceutical Platform; Renal Care Technology Platform; Digital Health & Data Platform; Intelligent Care Robotics Infrastructure
FY2026 Priorities: HIT-1 clinical validation and regulatory pathway; Diabrane commercialisation; digital health integration; pharmaceutical registrations; biodegradable medical consumables contract commencing June 2026